Risk of chemotherapy-induced febrile neutropenia by day of pegfilgrastim prophylaxis in US clinical practice from 2010 to 2015

References

• Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187-205
   PubMed Web of Science ®Google Scholar
• Caggiano V, Weiss RV, Rickert TS, et al. Incidence, cost and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 2005;103:1916-24
   PubMed Web of Science ®Google Scholar
• Lyman GH, Michels SL, Reynolds MW, et al. Risk of mortality in patients with cancer who experience febrile neutropenia. Cancer 2010;116:5555-63
   PubMed Web of Science ®Google Scholar
• Kuderer NM, Dale DC, Crawford J, et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006;106:2258-66
   PubMed Web of Science ®Google Scholar
• Bonadonna G, Moliterni A, Zambetti M, et al. 30 years’ follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ 2005;330:217
   PubMed Web of Science ®Google Scholar
• Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol 2003;21:4524-31
   PubMed Web of Science ®Google Scholar
• Kwak LW, Halpern J, Olshen RA, et al. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol 1990;8:963-77
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines): myeloid growth factors. Available at: https://www.nccn.org/professionals/physician_gls/pdf/myeloid_growth.pdf [Last accessed 7 April 2017]
   Google Scholar
• Weycker D, Li X, Tzivelekis S, et al. Burden of chemotherapy-induced febrile neutropenia hospitalizations in US clinical practice, by use and patterns of prophylaxis with colony-stimulating factor. Support Care Canc 2017;25:439-47
   PubMed Web of Science ®Google Scholar
• Tan H, Tomic K, Hurley D, et al. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study. Curr Med Res Opin 2011;27:79-86
   PubMed Web of Science ®Google Scholar
• Weycker D, Malin J, Barron R, et al. Comparative effectiveness of filgrastim, pegfilgrastim, and sargramostim as prophylaxis against hospitalization for neutropenic complications in cancer chemotherapy patients. Am J Clin Oncol 2011;35:267-74
   Web of Science ®Google Scholar
• Morrison VA, Wong M, Hershman D, et al. Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3–4 week chemotherapy regimens in community oncology practices. J Manag Care Pharm 2007;13:337-48
   PubMed Web of Science ®Google Scholar
• Amgen Inc. Neulasta (Pegfilgrastim) Prescribing Information. Thousand Oaks, CA: Amgen Inc., 2009
   Google Scholar
• Green MD, Koelbl H, Baselga J, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003;14:29-35
   PubMed Web of Science ®Google Scholar
• Holmes FA, O’Shaughnessy JA, Vukelja S, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 2002;20:727-31
   PubMed Web of Science ®Google Scholar
• Vogel CL, Wojtukiewicz MZ, Carroll RR, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 2005;23:1178-84
   PubMed Web of Science ®Google Scholar
• Weycker D, Li X, Figueredo J, et al. Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter? Support Care Canc 2016;24:2309-16
   PubMed Web of Science ®Google Scholar
• Weycker D, Edelsberg J, Kartashov A, et al. Risk and healthcare costs of chemotherapy-induced neutropenic complications in women with metastatic breast cancer. Chemotherapy 2012;58:8-18
   PubMed Web of Science ®Google Scholar
• Schuman S, Lambrou N, Robson K, et al. Pegfilgrastim dosing on same day as myelosuppressive chemotherapy for ovarian or primary peritoneal cancer. Support Oncol 2009;7:225-8
   PubMedGoogle Scholar
• Lokich J. Same day pegfilgrastim and CHOP chemotherapy for non-Hodgkin lymphoma. Am J Clin Oncol 2006;29:361-3
   PubMed Web of Science ®Google Scholar
• Hoffman P. Administration of pegfilgrastim on the same day or next day of chemotherapy. ASCO American Society of Clinical Oncology Annual Meeting #8137, 2005 (Abstract)
   Google Scholar
• Bennett CL, Djulbegovic B, Norris LB, Armitage JO. Colony-stimulating factors for febrile neutropenia during cancer therapy. N Engl J Med 2013;368:1131-9
   PubMed Web of Science ®Google Scholar
• Burris III H, Belani C, Kaufman P, et al. Pegfilgrastim on the same day versus next day of chemotherapy in patients with breast cancer, non-small-cell lung cancer, ovarian cancer, and non-Hodgkin’s lymphoma: results of four multicenter, double-blind, randomized phase II studies. J Oncol Pract 2010;6:133-40
   PubMedGoogle Scholar
• Skarlos DV, Timotheadou E, Galani E, et al. Pegfilgrastim administered on the same day with dose-dense adjuvant chemotherapy for breast cancer is associated with a higher incidence of febrile neutropenia as compared to conventional growth factor support: matched case–control study of the Hellenic Cooperative Oncology Group. Oncology 2009;77:107-12
   PubMed Web of Science ®Google Scholar
• Cheng C, Gallagher EM, Yeh J-Y, et al. Rates of febrile neutropenia with pegfilgrastim on same day versus next day of CHOP with or without rituximab. Anticancer Drugs 2014;25:964-9
   PubMed Web of Science ®Google Scholar
• Whitworth JM, Matthews KS, Shipman KA, et al. The safety and efficacy of day 1 versus day 2 administration of pegfilgrastim in patients receiving myelosuppressive chemotherapy for gynecologic malignancies. Gynecol Oncol 2009;112:601-4
   PubMed Web of Science ®Google Scholar
• Gupta NK, Thorpe S, Vanderhoff P, et al. Pegfilgrastim can be effectively administered the same day as chemotherapy to prevent neutropenia-related complications. J Clin Oncol 2007;25:19571
   Web of Science ®Google Scholar
• Billingsley CC, Jacobson SN, Crafton SM, et al. Evaluation of the hematologic safety of same day versus standard administration (24- to 72-hour delay) of pegfilgrastim in gynecology oncology patients undergoing cytotoxic chemotherapy. Int J Gynecol Canc 2015;25:1331-6
   PubMed Web of Science ®Google Scholar
• Ibrahim Z, Hughes J, McQuillan A, et al. The effect of pegylated granulocyte-colony stimulating factor (GCSF; pegfilgrastim, Neulasta) administration timing in relation to the chop or choplike regimen administration timing in non-Hodgkin’s lymphoma (NHL) patients on development of neutropenia. Asia-Pacific J Clin Oncol 2011;7:135-6
   Google Scholar
• Karol J, Rybicki L, Sweetenham J, et al. Similar incidence of febrile neutropenia with same-day versus subsequent day G-CSF administration in non-Hodgkin lymphoma patients receiving R-CHOP chemotherapy. Conference: 55th Annual Meeting of the American Society of Hematology, ASH, Blood 2013;122:4357
   Google Scholar
• Linot B, Augereau P, Breheret R, et al. Efficacy and safety of early G-CSF administration in patients with head and neck cancer treated by docetaxel-cisplatin and 5-fluorouracil (DCF protocol): a retrospective study. Support Care Canc 2014;22:2831-7
   PubMed Web of Science ®Google Scholar
• Li Y, Klippel Z, Shih X, et al. Trajectory of absolute neutrophil counts in patients treated with pegfilgrastim on the day of chemotherapy versus the day after chemotherapy. Canc Chemother Pharmacol 2016;77:703-12
   PubMed Web of Science ®Google Scholar
• Siefker-Radtke AO, Campbell MT, Munsell MF, et al. Front-line treatment with gemcitabine, paclitaxel, and doxorubicin for patients with unresectable or metastatic urothelial cancer and poor renal function: final results from a phase II study. Urology 2016;89:83-9
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services (2009) Code of Federal Regulations: Title 45, public welfare; Part 46, protection of human subjects. Available at: http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.html [Last accessed 4 July 2013]
   Google Scholar
• Weycker D, Li X, Edelsberg J, et al. Risk and consequences of chemotherapy-induced febrile neutropenia in patients with metastatic solid tumors. J Oncol Pract 2015;11:47-54
   PubMed Web of Science ®Google Scholar
• Langeberg W, Siozon CC, Page JH, et al. Use of pegfilgrastim primary prophylaxis and risk of infection, by chemotherapy cycle and regimen, among patients with breast cancer or non-Hodgkin’s lymphoma. Support Care Canc 2014;22:2167-75
   PubMed Web of Science ®Google Scholar
• Weycker D, Sofrygin O, Seefeld K, et al. Technical evaluation of methods for identifying chemotherapy-induced febrile neutropenia in healthcare claims databases. BMC Health Services Res 2013;13:60
   PubMed Web of Science ®Google Scholar
• Stephens JM, Bensink M, Bowers C, Hollenbeak CS. Travel burden associated with granulocyte colony-stimulating factor administration in a Medicare aged population: a geospatial analysis. Curr Med Res Opin 2017;31:1-10
   Google Scholar
• Lyman GH, Morrison VA, Dale DC, et al. Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin’s lymphoma receiving CHOP chemotherapy. Leuk Lymphoma 2003;44:2069-76
   PubMed Web of Science ®Google Scholar